Friday, February 18, 2022, San Francisco, California, 6:30 PM – 8:00 PM Pacific Time (9:30 PM – 11:00 PM Eastern Time)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Bladder Cancer

Part 2 of a 2-Part CME Symposium Series Held in Conjunction with the 2022 Genitourinary Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
6:15 PM – 6:30 PM — Registration
6:30 PM – 8:00 PM — Educational Dinner Meeting

Meeting Room
Golden Gate – Salon C (B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Shilpa Gupta, MD
Associate Professor
Director, Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio

Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale School of Medicine
New Haven, Connecticut


Guru Sonpavde, MD
Bladder Cancer Director
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Sumanta Kumar Pal, MD
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope
Duarte, California


This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, and Gilead Sciences Inc.
Program Schedule — Pacific Time
6:15 PM – 6:30 PM — Registration
6:30 PM – 8:00 PM — Educational Dinner Meeting

MODULE 1: Integrating Novel Agents into the Treatment Paradigm for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Pal

  • Long-term follow-up from the KEYNOTE-057 trial evaluating pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who are unresponsive or refractory to BCG therapy
  • Ongoing Phase III trials (eg, ALBAN, POTOMAC, KEYNOTE-676, CheckMate 7G8) evaluating anti-PD-1/PD-L1 antibodies in combination with BCG in NMIBC
  • Key efficacy and safety results from the Phase III CheckMate 274 trial comparing nivolumab to placebo after surgery in high-risk muscle-invasive bladder cancer (MIBC); optimal integration of nivolumab into current treatment paradigms
  • Rates of pathologic complete response and other clinically relevant outcomes achieved in early trials evaluating neoadjuvant anti-PD-1/PD-L1 antibody therapy for resectable MIBC
  • Early data with and ongoing trials of neoadjuvant and adjuvant anti-PD-1/PD-L1 antibodies combined with radiation therapy and other systemic therapies for patients with MIBC
  • Emerging results from cohort H of Study EV-103 evaluating neoadjuvant treatment with enfortumab vedotin monotherapy for cisplatin-ineligible patients with MIBC

MODULE 2: Current and Future Front-Line Management of Metastatic UBC (mUBC) — Dr Gupta

  • Current clinical role of atezolizumab and pembrolizumab as first-line treatment for mUBC; importance of chemotherapy eligibility and PD-L1 status in patient selection for this strategy
  • Published efficacy and safety data with avelumab maintenance after front-line chemotherapy for patients with mUBC
  • Key efficacy and safety findings from the Phase II EV-103 study evaluating first-line pembrolizumab in combination with enfortumab vedotin for patients with mUBC
  • Available data with anti-PD-1/PD-L1 antibodies combined with anti-CTLA-4 antibodies for previously untreated mUBC; ongoing Phase III trials (eg, CheckMate 901, NILE) evaluating dual checkpoint inhibitor therapy alone or in combination with chemotherapy
  • Other promising investigational strategies in the up-front setting (eg, anti-PD-1/PD-L1 antibodies combined with chemotherapy, erdafitinib/cetrelimab, PARP inhibitors)

MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Petrylak

  • Key efficacy and safety findings with enfortumab vedotin for patients with progressive mUBC (eg, EV-301, EV-201 cohort 2)
  • Published efficacy and safety data with erdafitinib for patients with mUBC and susceptible FGFR3 or FGFR2 genetic alterations
  • Key efficacy and safety findings from the Phase II TROPHY U-01 trial leading to the FDA approval of sacituzumab govitecan for patients with progressive mUBC
  • Emerging results from cohort 3 of TROPHY U-01 combining sacituzumab govitecan and pembrolizumab
  • Mechanism of action of and available efficacy and safety findings with the antibody-drug conjugate disitamab vedotin for patients with HER2-overexpressing mUBC
  • Other promising investigational agents and strategies for the management of mUBC

MODULE 4: Tolerability/Toxicity of Novel Treatment Strategies and Practical Considerations in the Management of UBC — Dr Sonpavde

  • Algorithms for the management of immune-related adverse events in patients receiving checkpoint inhibitor therapy; differences, if any, between the nonmetastatic and metastatic settings
  • Rates of and management approaches for enfortumab vedotin-related adverse events (eg, peripheral neuropathy, rash, hyperglycemia)
  • Pathophysiology of rare but severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis in patients receiving enfortumab vedotin
  • Incidence and management of common toxicities reported with erdafitinib (hyperphosphatemia, nail changes, stomatitis, hand-foot syndrome, dry skin, et cetera)
  • Similarities and differences between the ocular toxicities observed with enfortumab vedotin and erdafitinib; implications for monitoring and management
  • Frequency, severity and recommended algorithms for the management of side effects related to sacituzumab govitecan in mUBC (eg, neutropenia, diarrhea)

Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of urothelial bladder cancer (UBC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recall available data supporting the use of anti-PD-1 antibody therapy for BCG-resistant, high-risk, non-muscle-invasive bladder cancer (NMIBC), and determine how this strategy can be appropriately integrated into current care.
  • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this treatment strategy.
  • Appreciate the impact of biologic and patient-specific factors on the selection and sequencing of treatment for patients with metastatic UBC (mUBC).
  • Evaluate available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed mUBC.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients who may benefit from these approaches.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
  • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for patients with NMIBC, MIBC and mUBC.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Gupta — Advisory Committee: Aveo Pharmaceuticals, EMD Serono Inc, Gilead Sciences Inc, Lilly, Pfizer Inc; Consulting Agreements: Aveo Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Gilead Sciences Inc, Janssen Biotech Inc, Lilly, Pfizer Inc; Ownership Interest: Nektar; Speakers Bureau: Bristol-Myers Squibb Company, Gilead Sciences Inc, Janssen Biotech Inc, Seagen Inc. Dr Petrylak — Consulting Agreements: Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc; Contracted Research: Gilead Sciences Inc. Dr Sonpavde — Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc, Sanofi Genzyme, Scholar Rock, Seagen Inc; Consulting Agreements (Paid): AstraZeneca Pharmaceuticals LP, Debiopharm, EMD Serono Inc; Consulting Agreements (Unpaid): Bavarian Nordic, Bristol-Myers Squibb Company, G1 Therapeutics Inc, QED Therapeutics, Seagen Inc; Travel Cost: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; Writing/Editor Fees: Elsevier Practice Update Bladder Cancer Center of Excellence.

MODERATOR — Sumanta Kumar Pal, MD – No relevant conflicts of interest to disclose

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, and Gilead Sciences Inc.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate – Salon C (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2022 Genitourinary Cancers Symposium is taking place.

 

Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 6:00 PM on Friday, February 18th. If you are interested in attending, please visit our registration desk located outside the Golden Gate – Salon C (B2 Level) of the Marriott Marquis hotel (780 Mission Street) within walking distance of the Moscone Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.